Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study

Original Submission
8 Sep 2021 Submitted Original manuscript
3 Oct 2021 Reviewed Reviewer Report
10 Oct 2021 Reviewed Reviewer Report
29 Oct 2021 Author responded Author comments - Elisenda Pomares
Resubmission - Version 2
29 Oct 2021 Submitted Manuscript version 2
2 Nov 2021 Author responded Author comments - Elisenda Pomares
Resubmission - Version 3
2 Nov 2021 Submitted Manuscript version 3
14 Nov 2021 Reviewed Reviewer Report
7 Dec 2021 Reviewed Reviewer Report
23 Dec 2021 Author responded Author comments - Elisenda Pomares
Resubmission - Version 4
23 Dec 2021 Submitted Manuscript version 4
Publishing
31 Jan 2022 Editorially accepted
17 Feb 2022 Article published 10.1186/s12913-022-07567-5

You can find further information about peer review here.

Back to article page